ATE240119T1 - Antigen präsentierendes system und aktivierung von t-zellen - Google Patents

Antigen präsentierendes system und aktivierung von t-zellen

Info

Publication number
ATE240119T1
ATE240119T1 AT96909631T AT96909631T ATE240119T1 AT E240119 T1 ATE240119 T1 AT E240119T1 AT 96909631 T AT96909631 T AT 96909631T AT 96909631 T AT96909631 T AT 96909631T AT E240119 T1 ATE240119 T1 AT E240119T1
Authority
AT
Austria
Prior art keywords
cells
activation
presentation system
antigen presentation
molecules
Prior art date
Application number
AT96909631T
Other languages
English (en)
Inventor
Zeling Cai
Jonathan Sprent
Anders Brunmark
Michael Jackson
Per A Petterson
Alain M D Luxembourg Ph D
Didier Jean Leturcq
Ann M Moriarty
Original Assignee
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Inst filed Critical Scripps Research Inst
Application granted granted Critical
Publication of ATE240119T1 publication Critical patent/ATE240119T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0601—Invertebrate cells or tissues, e.g. insect cells; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/428—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/50—Coculture with; Conditioned medium produced by invertebrate cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/99—Coculture with; Conditioned medium produced by genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18811—Sendai virus
    • C12N2760/18822—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/75—Vector systems having a special element relevant for transcription from invertebrates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT96909631T 1995-03-08 1996-03-08 Antigen präsentierendes system und aktivierung von t-zellen ATE240119T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40033895A 1995-03-08 1995-03-08
PCT/US1996/003249 WO1996027392A1 (en) 1995-03-08 1996-03-08 Antigen presenting system and methods for activation of t-cells

Publications (1)

Publication Number Publication Date
ATE240119T1 true ATE240119T1 (de) 2003-05-15

Family

ID=23583206

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96909631T ATE240119T1 (de) 1995-03-08 1996-03-08 Antigen präsentierendes system und aktivierung von t-zellen

Country Status (11)

Country Link
US (10) US6461867B1 (de)
EP (1) EP0814838B1 (de)
JP (2) JP3926842B2 (de)
AT (1) ATE240119T1 (de)
AU (1) AU720201B2 (de)
CA (1) CA2214649C (de)
DE (1) DE69628154T2 (de)
DK (1) DK0814838T3 (de)
ES (1) ES2201177T3 (de)
PT (1) PT814838E (de)
WO (1) WO1996027392A1 (de)

Families Citing this family (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE347103T1 (de) 1996-09-06 2006-12-15 Ortho Mcneil Pharm Inc Reinigung von antigenspezifischen t-zellen
DE69942100D1 (de) * 1998-10-20 2010-04-15 Androclus Technologies S R L I Künstliche antigen-spezifischen zellen und zugehörige verfahren
US7521202B2 (en) * 1999-12-17 2009-04-21 The Board Of Regents Of The University Of Oklahoma Method and apparatus for the production of soluble MHC antigens and uses thereof
US20060276629A9 (en) * 1999-12-17 2006-12-07 Hildebrand William H Purification and characterization of soluble human HLA proteins
US20060035338A1 (en) * 1999-12-17 2006-02-16 Pure Protein Llc Method and apparatus for the production of soluble MHC antigens and uses thereof
US7541429B2 (en) * 2000-10-10 2009-06-02 The Board Of Regents Of The University Of Oklahoma Comparative ligand mapping from MHC positive cells
US20030166057A1 (en) * 1999-12-17 2003-09-04 Hildebrand William H. Method and apparatus for the production of soluble MHC antigens and uses thereof
AUPQ755300A0 (en) * 2000-05-17 2000-06-08 Monash University Immune potentiating compositions
US20090062512A1 (en) * 2000-10-10 2009-03-05 Hildebrand William H Comparative ligand mapping from MHC class I positive cells
US20070099182A1 (en) * 2000-10-10 2007-05-03 Hildebrand William H Comparative ligand mapping from MHC class I positive cells
US20070026433A1 (en) * 2001-03-09 2007-02-01 Hildebrand William H Epitope testing using soluble HLA
US20020122820A1 (en) * 2001-01-16 2002-09-05 Hildebrand William H. Soluble MHC artificial antigen presenting cells
US20040071671A1 (en) 2001-02-20 2004-04-15 Leturcq Didier J. Cell therapy method for the treatment of tumors
US20030077248A1 (en) * 2001-02-20 2003-04-24 Ann Moriarty Cell therapy method for the treatment of tumors
EP1399850A2 (de) * 2001-02-21 2004-03-24 The Board of Regents of The University of Oklahoma Hla-liganden-datenbank mit vorausschauenden algorithmen und verfahren zum erstellen und verwenden dieser datenbank
CA2440399C (en) * 2001-03-09 2008-11-18 Rico Buchli Epitope testing using hla
FR2821947B1 (fr) * 2001-03-12 2003-05-16 Canon Kk Procede et dispositif de validation de parametres definissant une image
EP2107110A3 (de) 2001-05-15 2011-10-26 Ortho-McNeil Pharmaceutical, Inc. Ex-vivo-Priming zur Erzeugung zytotoxischer T-Lymphozyten, die für Nicht-Tumorantigene spezifisch sind, zur Behandlung von Autoimmunerkrankungen und Allergien
US20030134415A1 (en) * 2001-09-19 2003-07-17 Gruenberg Micheal L. Th1 cell adoptive immunotherapy
US20030175242A1 (en) * 2001-09-17 2003-09-18 Micheal Gruenberg Cell therapy system
US20030134341A1 (en) * 2001-09-19 2003-07-17 Medcell Biologics, Llc. Th1 cell adoptive immunotherapy
US7955845B2 (en) 2001-11-20 2011-06-07 Dana Farber Cancer Institute, Inc. Modified antigen-presenting cells
WO2003057852A2 (en) * 2001-12-18 2003-07-17 Hildebrand William H Purification and characterization of hla proteins
US20040126829A1 (en) * 2001-12-18 2004-07-01 Hildebrand William H. Anti-HLA assay and methods
CA2473909A1 (en) * 2002-01-15 2003-07-24 Advanced Cell Technology, Inc. Cloning b and t lymphocytes
US20030175272A1 (en) * 2002-03-07 2003-09-18 Medcell Biologics, Inc. Re-activated T-cells for adoptive immunotherapy
DE10231655A1 (de) * 2002-07-12 2004-02-26 Blasticon Biotechnologische Forschung Gmbh Transplantat-Akzeptanz induzierende Zellen monozytären Ursprungs, sowie deren Herstellung und Verwendung
AU2003270876A1 (en) * 2002-09-24 2004-04-19 Rico Buchli Anti-hla assay and methods
US20040072262A1 (en) * 2002-10-11 2004-04-15 Montero-Julian Felix A. Methods and systems for detecting MHC class I binding peptides
CA2520675A1 (en) * 2003-03-24 2004-10-07 The Government Of The United States Of America, As Represented By The Se Cretary, Department Of Health And Human Services Identification, quantification, and characterization of t cells and t cell antigens
US20040248205A1 (en) * 2003-04-16 2004-12-09 Stern Lawrence J. Major histocompatibility complex (MHC)-peptide arrays
PL379549A1 (pl) * 2003-07-11 2006-10-16 Blasticon Biotechnologische Forschung Gmbh Autologiczne, indukujące tolerancję na antygeny własne komórki pochodzenia monocytarnego oraz ich zastosowanie w preparatach farmaceutycznych
JP2007511760A (ja) * 2003-11-03 2007-05-10 ベックマン コールター インコーポレーティッド Ｍｈｃ結合ペプチドを検出するための溶液ベースの方法
US20050130897A1 (en) * 2003-12-11 2005-06-16 Ma Jian-Xing Compounds useful in inhibiting vascular leakage, inflammation and fibrosis and methods of making and using same
US9090673B2 (en) * 2003-12-12 2015-07-28 City Of Hope Synthetic conjugate of CpG DNA and T-help/CTL peptide
PL2573166T3 (pl) * 2004-02-26 2016-11-30 Sposoby otrzymywania komórek T do terapii komórkowej
US7592431B2 (en) * 2004-02-26 2009-09-22 Immunovative Therapies, Ltd. Biodegradable T-cell Activation device
DK1749090T3 (en) 2004-03-01 2017-09-04 Immunovative Therapies Ltd CELL THERAPY FORMULATION PROCEDURE AND COMPOSITION
EP1766393A4 (de) * 2004-05-07 2008-06-18 Beckman Coulter Inc Mhc-brückensystem zum nachweis der ctl-vermittelten lyse antigenpräsentierender zellen
EP1781313A4 (de) * 2004-06-17 2009-08-26 Beckman Coulter Inc Mycobacterium tuberculosis epitope und anwendungsverfahren dafür
WO2006081620A1 (en) * 2005-02-02 2006-08-10 Newsouth Innovations Pty Limited Cd4+ cd25+ t-cells activated to a specific antigen
EP1712615A1 (de) * 2005-04-15 2006-10-18 Txcell In vitro Herstellung einer Zellpopulation mittels Nährzellen
US7838503B2 (en) * 2005-06-15 2010-11-23 Children's Medical Center Corporation Methods for extending the replicative lifespan of cells
DK1739166T3 (da) * 2005-07-01 2011-10-10 Txcell S A Fremstilling af fødevare- eller autoantigen-specifikke Tr1-celler fra en leukocyt- eller PBMC-population
RU2447900C2 (ru) 2006-03-01 2012-04-20 Янссен Фармацевтика Н.В. Лечение рака, комбинирующее лимфоистощающее вещество с цтл и цитокинами
EP2052076A4 (de) 2006-08-02 2010-07-14 Newsouth Innovations Pty Ltd Verfahren zur identifizierung von gegen ein antigen aktivierten, cd8 exprimierenden cd4+cd25+-t-zellen
BRPI0720342A2 (pt) * 2006-10-04 2018-09-18 Janssen Pharmaceutica N.V. preparado de células apresentadoras de antígenos artificiais e seu uso em terapias celulares.
EP2300023A2 (de) * 2008-05-16 2011-03-30 Genelux Corporation Mikroorganismen zur prävention und behandlung von neoplasien neben einer zelltherapie
US8075895B2 (en) 2009-09-22 2011-12-13 Janssen Pharmaceutica N.V. Identification of antigenic peptides from multiple myeloma cells
CA2783876C (en) 2009-12-11 2018-04-03 Proyecto De Biomedicina Cima, S.L. New conjugates and compositions for immunotherapy and antitumoral treatment
US9233156B2 (en) 2011-05-03 2016-01-12 Immunovative Therapies Ltd. Induction of IL-12 using immunotherapy
CA2838041C (en) 2011-05-03 2018-09-25 Immunovative Therapies, Ltd. Methods for handling biological drugs containing living cells
US8834889B2 (en) * 2011-08-29 2014-09-16 National Tsing Hua University Antigen presenting composition and use thereof
HUE047507T2 (hu) 2011-10-17 2020-04-28 Massachusetts Inst Technology Intracelluláris célbajuttatás
WO2013086500A1 (en) 2011-12-09 2013-06-13 The Johns Hopkins University Artificial antigen presenting cells having a defined and dynamic shape
WO2013163171A1 (en) 2012-04-24 2013-10-31 Kaufman Dan S Method for developing natural killer cells from stem cells
US9844582B2 (en) 2012-05-22 2017-12-19 Massachusetts Institute Of Technology Synergistic tumor treatment with extended-PK IL-2 and therapeutic agents
ES2828982T3 (es) 2013-05-14 2021-05-28 Univ Texas Aplicación humana de células t de receptor de antígeno quimérico (car) diseñadas
EP3848695A1 (de) 2013-08-16 2021-07-14 Massachusetts Institute Of Technology Selektive freisetzung von material an zellen
US20160320408A1 (en) 2013-12-19 2016-11-03 Opexa Therapeutics, Inc. Methods of t cell epitope profiling, making t cell compositions, and treating diseases
CN113234757B (zh) 2014-02-14 2024-10-29 得克萨斯州大学系统董事会 嵌合抗原受体及制备方法
EP3134437A1 (de) 2014-04-23 2017-03-01 Board of Regents, The University of Texas System Chimäre antigenrezeptoren (car) zur verwendung in der therapie und verfahren zur herstellung davon
KR20160145186A (ko) 2014-04-24 2016-12-19 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 입양 세포 요법 생성물을 생성하기 위한 유도 만능 줄기 세포의 응용
EP3212772A4 (de) 2014-10-31 2018-10-03 Massachusetts Institute of Technology Abgabe von biomolekülen an immunzellen
US10570186B2 (en) 2014-11-05 2020-02-25 Board Of Regents, The University Of Texas System Chimeric antigen receptors (CAR) to selectively target protein complexes
CA2964785A1 (en) 2014-11-05 2016-05-12 Board Of Regents, The University Of Texas System Gene modified immune effector cells and engineered cells for expansion of immune effector cells
WO2016077761A1 (en) 2014-11-14 2016-05-19 Massachusetts Institute Of Technology Disruption and field enabled delivery of compounds and compositions into cells
WO2016100977A1 (en) 2014-12-19 2016-06-23 The Broad Institute Inc. Methods for profiling the t-cel- receptor repertoire
CN107250373A (zh) 2015-01-12 2017-10-13 麻省理工学院 通过微流体递送实现的基因编辑
SG10201912910PA (en) 2015-07-09 2020-02-27 Massachusetts Inst Technology Delivery of materials to anucleate cells
EP3344575B1 (de) 2015-09-04 2020-04-15 SQZ Biotechnologies Company Intrazelluläres einbringen von biomolekülen in zellen mit einer zellwand
WO2017075147A1 (en) 2015-10-27 2017-05-04 Board Of Regents, The University Of Texas System Chimeric antigen receptor molecules and uses thereof
JP7591342B2 (ja) 2016-06-08 2024-11-28 プレシゲン，インコーポレイテッド Ｃｄ３３特異的キメラ抗原受容体
KR20230107408A (ko) 2016-07-29 2023-07-14 주노 쎄러퓨티크스 인코퍼레이티드 항-cd19 항체에 대한 항-이디오타입 항체
US10294454B2 (en) 2016-08-24 2019-05-21 General Electric Company Methods and kits for cell activation
US11883430B2 (en) 2016-11-09 2024-01-30 Musc Foundation For Research Development CD38-NAD+ regulated metabolic axis in anti-tumor immunotherapy
JP7288401B2 (ja) 2017-01-10 2023-06-07 プレシゲン，インコーポレイテッド 新規の遺伝子スイッチ発現系を介したポリペプチドの発現のモジュレーション
KR102565256B1 (ko) 2017-02-12 2023-08-08 바이오엔테크 유에스 인크. Hla 기반 방법 및 조성물, 및 이들의 용도
IL269716B2 (en) 2017-04-18 2025-07-01 Fujifilm Cellular Dynamics Inc Antigen-specific immune effector cells
JP7262403B2 (ja) 2017-06-07 2023-04-21 プレシゲン，インコーポレイテッド 新規の細胞タグの発現
AU2018304543A1 (en) * 2017-07-21 2020-02-13 Berkeley Lights, Inc. Antigen-presenting synthetic surfaces, covalently functionalized surfaces, activated T cells, and uses thereof
KR102823603B1 (ko) 2017-10-12 2025-06-23 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 면역요법을 위한 t 세포 수용체
CN111918661A (zh) 2018-02-21 2020-11-10 得克萨斯大学体系董事会 用于活化和扩增自然杀伤细胞的方法及其用途
CN112739712A (zh) 2018-09-11 2021-04-30 格罗宁根大学 具有可调孔径的生物纳米孔及其作为分析工具的用途
CA3112813A1 (en) * 2018-09-21 2020-03-26 Berkeley Lights, Inc. Functionalized well plate, methods of preparation and use thereof
WO2020069377A1 (en) * 2018-09-27 2020-04-02 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods of using lysine deacetylase (kdac) inhibition to generate antigen specific memory t cell responses for durable immunotherapy
EA202191463A1 (ru) 2018-11-28 2021-10-13 Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем Мультиплексное редактирование генома иммунных клеток для повышения функциональности и устойчивости к подавляющей среде
MX2021006393A (es) 2018-11-29 2021-10-13 Univ Texas Metodos para expansion ex vivo de celulas exterminadoras naturales y uso de las mismas.
MX2021007556A (es) 2018-12-21 2021-09-10 Biontech Us Inc Método y sistemas de predicción de epítopos específicos de hla de clase ii y caracterización de células t cd4+.
US20210038684A1 (en) 2019-06-11 2021-02-11 Alkermes Pharma Ireland Limited Compositions and Methods for Cancer Immunotherapy
EP3994245A1 (de) 2019-07-05 2022-05-11 Case Western Reserve University Priming-medium und verfahren für stammzellenkultur und -therapie
JP2023500671A (ja) 2019-11-06 2023-01-10 ベイラー カレッジ オブ メディスン がんのｔ細胞治療のための細胞傷害性エフェクターメモリーｔ細胞の産生方法
US20230079539A1 (en) 2020-02-10 2023-03-16 Board Of Regents, The University Of Texas System Methods for rapid cloning and expression of hla class i cells
JPWO2021172595A1 (de) 2020-02-28 2021-09-02
CA3175580A1 (en) 2020-04-15 2021-10-21 Heather C. Losey Immunostimulatory agents in combination with angiogenesis inhibitors
BR112022024027A2 (pt) 2020-05-27 2023-02-07 Antion Biosciences Sa Moléculas adaptadoras para redirecionar células t car para um antígeno de interesse
CN113913458A (zh) * 2020-07-09 2022-01-11 杭州优凯瑞医药科技有限公司 非病毒方法制备稳定高表达嵌合受体的nk细胞
WO2022140759A2 (en) 2020-12-23 2022-06-30 Janssen Biotech, Inc. Neoantigen peptide mimics
EP4284409A4 (de) 2021-02-01 2025-03-26 The Board of Trustees of the Leland Stanford Junior University Bestimmung und verwendungen von cd8+-t-zellepitopen
WO2022187280A1 (en) 2021-03-01 2022-09-09 Dana-Farber Cancer Institute, Inc. Personalized redirection and reprogramming of t cells for precise targeting of tumors
WO2023211972A1 (en) 2022-04-28 2023-11-02 Medical University Of South Carolina Chimeric antigen receptor modified regulatory t cells for treating cancer
WO2024091124A1 (en) 2022-10-28 2024-05-02 Rijksuniversiteit Groningen Nanopore-based analysis of proteins

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5858358A (en) * 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US5580562A (en) * 1990-03-14 1996-12-03 Board Of Regents The University Of Texas System Preparations and uses thereof for immunosuppression
US5637483A (en) * 1991-10-04 1997-06-10 Whitehead Institute For Biomedical Research Irradiated tumor cell vaccine engineered to express GM-CSF
US5314813A (en) 1992-02-19 1994-05-24 Scripps Research Institute Drosophila cell lines expressing genes encoding MHC class I antigens and B2-microglobulin and capable of assembling empty complexes and methods of making said cell lines
US5731160A (en) * 1992-05-26 1998-03-24 Rijksuniversiteit Leiden Induction of antigen specific T-lymphocyte responses by stimulation with peptide loaded MHC class I molecules on antigen processing defective mammalian cell lines
US5397703A (en) * 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
US5763585A (en) * 1993-10-13 1998-06-09 Anergen, Inc. Method of making MHC-peptide complexes using metal chelate affinity chromatography
US6090587A (en) * 1993-10-25 2000-07-18 Corixa Corporation Prokaryotic expression of MHC proteins
US5595881A (en) * 1994-08-09 1997-01-21 Anergen, Inc. Method for the detection of antigen presenting cells
US6045802A (en) * 1994-10-03 2000-04-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Enhanced immune response to an antigen by a composition of a recombinant virus expressing the antigen with a recombinant virus expressing an immunostimulatory molecule
US20040176358A1 (en) * 1999-04-30 2004-09-09 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof

Also Published As

Publication number Publication date
US20050152916A1 (en) 2005-07-14
EP0814838A4 (de) 2000-04-12
PT814838E (pt) 2003-09-30
US20030072796A1 (en) 2003-04-17
EP0814838B1 (de) 2003-05-14
AU720201B2 (en) 2000-05-25
WO1996027392A1 (en) 1996-09-12
ES2201177T3 (es) 2004-03-16
JP4629650B2 (ja) 2011-02-09
US20030077318A1 (en) 2003-04-24
US6251627B1 (en) 2001-06-26
US6225042B1 (en) 2001-05-01
JP2007161719A (ja) 2007-06-28
CA2214649C (en) 2007-06-12
US6362001B1 (en) 2002-03-26
US20030077708A1 (en) 2003-04-24
CA2214649A1 (en) 1996-09-12
JPH11501516A (ja) 1999-02-09
EP0814838A1 (de) 1998-01-07
DE69628154T2 (de) 2004-03-18
US6255073B1 (en) 2001-07-03
US6828150B2 (en) 2004-12-07
JP3926842B2 (ja) 2007-06-06
DE69628154D1 (de) 2003-06-18
AU5306096A (en) 1996-09-23
US6461867B1 (en) 2002-10-08
US20030138946A1 (en) 2003-07-24
DK0814838T3 (da) 2003-09-15

Similar Documents

Publication Publication Date Title
ATE240119T1 (de) Antigen präsentierendes system und aktivierung von t-zellen
ATE347588T1 (de) Systeme zur präsentation von mhc-antigenen der klasse ii und verfahren zur aktivierung von cd4?+-t-lymphozyten
WO1995011008A3 (en) Methods and compositions for microencapsulation of adjuvants
DE69535328D1 (de) In-vitro wachstum von langerhans'schen inseln und ihre verwendungen
HUP9802538A2 (hu) Vektorok és eljárások helyspecifikus rekombináció előidézésére
DK1634949T3 (da) Fremgangsmåde til at generere aktiverede T-celler og antigen-inkuberede antigen-præsenterende celler
DK0975333T3 (da) Alginatgel med langvarig frigörelse
YU48440B (sh) Mutanti ili varijante bacillus thuringiensis-a koje proizvode visoke prinose delta endotoksina
DK66692A (da) En mammal cytokin, il-11
AU3272395A (en) Cloning and regulation of an endothelial cell protein c/activated protein c receptor
NO962073D0 (no) Amfifiliske imidazoliniumderivater
ES2153468T3 (es) Preparaciones cosmeticas y/o farmaceuticas con sensacion cutanea mejorada.
EP0952772A4 (de) Zusammensetzungen und verwendungsmethoden von einkernigen phagozyten zur forderung der axonalen regeneration
MX9802730A (es) Agonistas receptores hematopoyeticos multifuncionales.
WO1990007321A3 (en) Lymphocyte receptor homing sequences and their uses
NO960710D0 (no) Nye tripeptider nyttige i immun- og CNS-terapi
MX9202643A (es) Peptidos utiles en la regulacion de los sistemas inmunologico y nervioso.
NO922304L (no) Eliminering av aktiverte lymfocytter
ATE221079T1 (de) Zusammensetzungen und verfahrenen zur synthese von organophosphorus derivaten
DE69835615D1 (de) Induzierte zelluläre immunitität durch aktivierung der th1 und unterdrückung der th2 antwort durch macrophhagen
SU877505A1 (ru) Импульсный стабилизированный источник питани
EP1032418A4 (de) Kompakte replikons des epstein-barr-virus.
DK0484331T3 (da) Enkeltkrystaller af -g(b)-phenylpropiophenoner
AU1799097A (en) Presentation of antigen, introduced into the cells by stimulation of macropinocytosis
SI0969865T1 (sl) Sistem za prikaz mhc razred ii antigenov in postopek za aktiviranje cd4? + t celic

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0814838

Country of ref document: EP